Articles On Race Oncology (ASX:RAC)

    ASX edges down in a quiet market Pilbara Minerals falls 5pc as share block sale is reported Westpac sells auto finance unit for up to $1.6 billion   The ASX has lifted slightly on Thursday, up by 0.1%, as traders remain cautious amid...

Island Pharmaceuticals undertakes a $3.5m capital raise strongly supported by cornerstone investors All subjects dosed in the Phase 2a component of Island’s Phase 2a/b PROTECT clinical trial for dengue fever The study capitalises on years...

Big biotech names support Island Therapeutics raising Radiopharm eyes FDA approval to start a therapeutic pan-cancer trial Truscreen’s cervical cancer diagnostic cracks a nice mention   Health Check is renowned biotech journo Tim Boreham’...

Healthcare stocks are doing relatively well globally in 2024
 The sector could see more recovery as Fed cuts rates
 How ASX biotechs performed in the month of September   The S&P 500 Health Care Index, a key world benchmark for health...

Stockhead joined with IR Department and Morgans for HealthInvest 2024 in Sydney last week The event highlighted some of ASX’s leading and up-and-coming biotech and life sciences companies Imricor Medical Systems, Race Oncology, Clarity Pha...

ASX health stocks dropped 1.74% in the past five days, while the broader markets rose 1.55% Power confident US Fed’s 50 basis points cut in cash rate this week will bring more optimism to the sector  Morgans, investor relations firm IR Dep...

ASX health stocks dropped 1.22% in the past four days, while the broader markets fell 1.35% Morgans downgrades Ramsay Health Care following its FY24 results, believes a ‘near-term earnings recovery looks challenging’ Percheron reports posi...

Stockhead’s Fraser Palamara sits down with new Race Oncology (ASX:RAC) executive chair Dr Peter Smith to get the short end of the long story on the company’s latest news. A board rework has been taken by investors in great stride, and Dr Sm...

ASX health stocks down in August and trail the broader market in 2024 CSL up 6,000pc since listing; sector outpaced benchmark 10x since 2006 AI is revolutionising healthcare, boosting diagnosis and treatment   The ASX Healthcare Index (AS...

Race Oncology hails significant FY24 with several key milestones achieved First batch of (cGMP) manufacturing and toxicology study successfully completed for Race’s new bisantrene formulation RC220 Preclinical work in the past year has de...

Aussie stocks dropped despite Wall Street edging up ahead of Nvidia’s report Inflation eased to 3.5pc, impacting rate cut predictions Fortescue and Flight Centre reported gains; Woolworths and Tabcorp faced losses   Aussie stocks dropped...

The ASX200 closed down 0.17% at 8,071 points as the market awaits local inflation data for July tomorrow. Energy finished the strongest performer up around 2.3%, followed by Materials around 0.8%. Information Technology shed around 1.3%,...

ASX healthcare stocks showed mixed results following the release of their most recent financials on Tuesday. Three companies in particular stand out, with two finishing in the green and one in the red. Integral Diagnostics Ltd (ASX: I...

Stockhead joins with IR Department and Morgans for HealthInvest 2024 in Sydney in September Event to highlight some of ASX’s leading up-and-coming health and life sciences companies Clarity Pharmaceuticals, Percheron Therapeutics, Imricor,...

S&P/ASX 200 Health Care index up 5pc in July, 9.5pc YTD Health sector gains momentum with expected Fed rate cuts; ResMed seen as a strong buy And ASX healthcare winners and losers in July   The S&P/ASX 200 Health Care index [XHJ]...

Stockhead’s Sarah Hughan sits down with Race Oncology’s (ASX:RAC) CEO Dr Daniel Tillett to get the short end of the long story on the company’s latest news. The biopharmaceutical company has successfully concluded a Phase 2 trial of its Bis...

The EMA has rejected the Alzheimer’s drug Leqembi, developed by Eisai and Biogen There is one ASX-listed company that collaborates with Eisai We take a look at the best performing ASX health stocks in the past month   In a major blow for...

ASX healthcare shares are in the red on Tuesday, with the S&P/ASX 200 Health Care Index (ASX: XHJ) down 0.46% and the S&P/ASX 200 Index (ASX: XJO) down 0.96% in early trading. As always, there are outliers, and these two ASX hea...

A2 Milk Company Ltd (ASX: A2M) shares ended up having a stellar finish to the year in FY24. In total, shares in the specialty milk company rose 38%, starting the year at $4.89 and closing the period at $6.77 apiece. Most of this was...

The 2024 Bioshares Biotech Summit being held in Fremantle from July 12-13 Morgans says conference likely to attract institutional and high net worth WA investors  Day one focus on new opportunities, finding the next blockbuster drug and re...

A2 Milk Co Ltd (ASX: A2M) shares are in the green today. Shares in the S&P/ASX 200 Index (ASX: XJO) dairy stock closed yesterday trading for $6.82. In morning trade on Thursday, shares are swapping hands for $6.88, up 0.8%. For so...

The ASX Health Care index saw a 4% increase in June Growth was driven by CSL and Cochlear Best biotechs in June were Actinogen, Optiscan and EZZ Life Science, amongst others    The S&P/ASX 200 Health Care index [XHJ] saw a 4% increase...

Tax-loss selling could be pile-driving fundamentally good companies into the ground. At least, that's what analysts at Macquarie think, prompting the team to name a handful of ASX shares to buy following the indiscriminate tax-driven sellin...

It was an unpleasant Wednesday for the S&P/ASX 200 Index (ASX: XJO) and most ASX shares this hump day. After enjoying a strong session yesterday, investors reversed course to...

  Race Oncology says non-clinical toxicology and safety studies of lead drug RC220 Bisantrene successfully completed RC220 demonstrated excellent safety profile, including safe administration via peripheral IV infusion Studies support star...

Cleo commences FDA process Cleo Diagnostics (ASX:COV) has announced significant progress in advancing its regulatory strategy for its pre-surgical triage test designed to detect ovarian cancer. Recently, Cleo conducted an initial pre-submis...

The S&P/ASX 200 Index (ASX: XJO) is having a tough time on Wednesday after a stronger than expected inflation reading. In afternoon trade, the benchmark index is down 1% to 7,758.4 points. Four ASX shares that are not letting that hold...

After closing up 1.4% on Tuesday, the S&P/ASX 200 Index (ASX: XJO) looks ready to give back most of those gains today. The benchmark index was down 0.5% at 11.30am AEST. Then, the Australian Bureau of Statistics (ABS) released May's Au...

Race Oncology Ltd (ASX: RAC) shares burst out of the gates on Wednesday morning. In early trade, the ASX healthcare stock was up as much as 15% to $1.96. The clinical stage biopharmaceutical company's shares have eased back a touch since th...

For biotech investors, the news of an approval by the US FDA is a genuinely exciting milestone. The FDA is the ultimate gatekeeper for the US pharmaceutical market, which is by far the world’s largest. Approval from the FDA not only validat...

With the S&P/ASX 200 Health Care Index (ASX: XHJ) dipping slightly into the red on Wednesday, it's been a different story for three individual ASX healthcare shares. Pro Medicus Limited (ASX: PME), Race Oncology Ltd (ASX: RAC), and...

S&P/ASX 200 Index (ASX: XJO) gold stocks enjoyed a blistering rally from late February through to late May this year. That rally was driven by a surge in the gold price. On 28 February, the yellow metal was trading for US$2,030 per oun...

The ASX 200 has finished the day up a per cent, after interest rates were kept on hold at 4.35%, firmly in line with predictions. Australia’s Big 4 and major investment banks were all calling for a June hold decision. However, Morgan St...

ASX rose  as the RBA held interest rates at 12-year high 4.35pc All 11 sectors on the ASX gained, with significant moves from Pilbara and Fortescue  ASX to launch first bitcoin-linked ETF on Thursday   Aussie stocks bounced back by +0.8%...

US FDA extends Rare Paediatric Disease Designation (RPDD) to Race Oncology’s novel RC220 bisantrene drug RPDD gives RC220 eligibility to receive a Priority Review Voucher (PRV) upon marketing approval PRV’s can be transferred or sold to ot...

The S&P/ASX 200 Index (ASX: XJO) is back on form on Tuesday and storming higher. In afternoon trade, the benchmark index is up 0.95% to 7,773.6 points. Four ASX shares that are rising more than most today are listed below. Here's why t...

Race Oncology Ltd (ASX: RAC) shares are roaring higher on Tuesday morning. In early trade, the ASX healthcare stock is up 11% to $1.94. Why is this ASX healthcare stock surging? Investors have been buying the clinical stage biopharmaceutica...

Race Oncology (ASX:RAC) has announced that the US FDA has extended Rare Paediatric Disease Designation to RC220 bisantrene to treat paediatric subtypes of acute myeloid leukemia.

Race Oncology (ASX:RAC) has announced a preclinical breakthrough in heart toxicity side effects caused by the carfilzomib, which had precluded the drug being administered to patients diagnosed with elevated cardiac risk factors. In work...

Race Oncology (ASX:RAC) has reported the results of preclinical work performed under contract by US-based Labcorp of a mouse model involving bisantrene in combination with carfilzomib.

The S&P/ASX 200 Index (ASX: XJO) endured a horror return for the short trading week this Tuesday, crashing by a depressing 1.33%. By the time the market closed, the ASX 200 was sittin...

Aussie shares slipped over 1pc after the King’s Birthday long weekend Mining and Real Estate sectors were the biggest losers among all 11 sectors Chinese EV stocks fell ahead of expected EU tariff hikes   Aussie shares slipped after the K...

  US FDA extends orphan drug designation to Race’s re-formulated RC220 bisantrene drug product for treatment of Acute Myeloid Leukemia Orphan drug designation has a range of commercial advantages including seven years market exclusivity in...

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated. Some might think Apple Inc's (NASDAQ: AAPL) best days are behind it. Revenue growth has ground to a halt. The company's bigge...

The S&P/ASX 200 Index (ASX: XJO) is having a very tough start to the week. In afternoon trade, the benchmark index is down 1.45% to 7,745.6 points. Four ASX shares that are not letting that hold them back today are listed below. Here's...

Orthocell (ASX:OCC) has taken a significant step forward in its efforts to introduce its SmrtGraft product to the Australian market. The company has submitted an application to the Therapeutic Goods Administration (TGA) seeking approval to...

The S&P/ASX 200 Index (ASX: XJO) is down 1.1% today, but you can't blame this rocketing ASX 200 share. Shares in the auto parts company closed on Friday trading for $4.36. In earlier trade on Tuesday, shares were swapping hands for $...

Race Oncology (ASX: RAC) has achieved a significant breakthrough with the US Food and Drug Administration (FDA) awarding orphan drug designation (ODD) to the company’s acute myeloid leukemia (AML) candidate bisantrene RC220. The coveted des...

Deciding which ASX dividend shares to buy can be a gruelling process. Luckily for income investors, analysts have done a lot of the hard work for you and picked out two they think are buys. Here's what they are saying about these dividend s...